Ebola outbreak outpaces response in DRC

The World Health Organization said on August 4 that the Democratic Republic of the Congo's Bundibugyo Ebola outbreak had become the largest recorded for that Ebola species even as vaccine and treatment trials were launched unusually quickly. CIDRAP reported a day later that the outbreak was also the fastest-growing on record, citing experts who said research had moved faster than in earlier Ebola emergencies. The contrast is the core public-health problem in central Africa this week: science is moving, but transmission is moving faster. Madagascar is facing a parallel strain on outbreak control. MedicalBrief reported on August 5 that the country had logged 3,022 mpox cases and 20 deaths after spread from one port city to several major coastal centers. In Angola, Cabinda province said it would widen mpox vaccination in border areas near the DRC in the coming days. ### Why is the Ebola outbreak in Congo drawing so much concern? (news.un.org) The Democratic Republic of the Congo is dealing with the largest-ever outbreak of Bundibugyo Ebola, according to the United Nations and WHO. A UN News report published August 4 said deaths and cases were rising in the outbreak, with trial results for new tools still likely months away. CIDRAP said on August 5 that experimental vaccines and treatments had entered testing faster than in previous Ebola outbreaks. (medicalbrief.co.za) But the same report said the pace of transmission was still outstripping response efforts, making the outbreak the fastest-growing in history for Ebola, according to the experts it cited. ### What is being tested in Congo right now? (news.un.org) WHO said on August 4 that efforts were under way toward the first vaccine for the Bundibugyo species of Ebola, alongside work on enhanced treatment options. The agency said results would not be immediate and could take months. The timing matters because Ebola response usually depends on speed: isolating cases, tracing contacts, and protecting health workers before chains of transmission widen. (cidrap.umn.edu) CIDRAP's August 5 report said the scientific rollout had been rapid by historical standards, but that operational response capacity remained under pressure as the caseload climbed. (news.un.org) ### How serious is the mpox outbreak in Madagascar? Madagascar has reported 3,022 mpox cases and 20 deaths, MedicalBrief said on August 5, after the virus spread from a single port city to some of the island's busiest coastal hubs. The report said experts feared the true scale could already be larger than official figures suggest. WHO's June 26 external situation report said Madagascar confirmed its first mpox case on December 17, 2025, and officially declared an outbreak on December 30, 2025. (cidrap.umn.edu) UNICEF said in a January 16 flash update that the outbreak involved mpox Clade 1b. ### Why is Angola focusing on Cabinda's border areas? Cabinda health secretary Rúbem Buco said the Angolan province would expand its mpox vaccination campaign with greater focus on areas bordering the Democratic Republic of the Congo. (medicalbrief.co.za) Reports published August 4 and August 6 said Cabinda had 109 confirmed cases and about 24 suspected cases, with no deaths reported. (who.int) More than 30,000 doses are expected in the province in the coming days, according to reports on the campaign announcement. The border focus reflects the geography of Cabinda, an Angolan exclave separated from the rest of the country and adjacent to the DRC and the Republic of the Congo. ### Where does the vaccine pipeline fit into this? (msn.com) Infection Control Today reported on August 5 that Tonix's investigational mpox vaccine TNX-801 had shown promising preclinical durability and single-dose protection in earlier company-presented data. The article described the findings as preclinical and framed them as a preparedness tool for future outbreaks rather than an immediate field intervention. (gdeltcloud.com) Tonix presented TNX-801 data at the World Vaccine Congress-Europe 2025, saying the candidate was designed for durable protection against mpox and smallpox and supported advancement toward clinical development. For now, the nearer milestones are more immediate: WHO has said Ebola trial results in Congo may take months, and Cabinda officials said additional mpox vaccine doses are expected in the coming days. (ir.tonixpharma.com) (infectioncontroltoday.com)